Ibrutinib + Venetoclax Promising for Chronic Lymphocytic Leukemia
Seventy-five percent of patients achieved a best response of bone marrow-undetectable measurable residual disease remission
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.